



## Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2016

This is to certify that:

Leica Biosystems Newcastle Ltd

Balliol Business Park West

Benton Lane

Newcastle upon Tyne

NE12 8EW United Kingdom

Facility ID Number: F000261

Holds Certificate No: MDSAP 696855

The company listed on this certificate has been audited to and found to conform with ISO 13485:2016 including the following country specific requirements:

Australia: Therapeutic Goods (Medical Devices) Regulations, 2002, Schedule 3 Part 1 (excluding Part 1.6) - Full

Quality Assurance Procedure

Brazil: RDC ANVISA n. 67/2009, RDC ANVISA n. 665/2022 - Good Manufacturing Practices, RDC ANVISA n.

551/2021

Canada: Medical Devices Regulations - Part 1 - SOR 98/282

Japan: MHLW MO No 169 (2004), as amended by MHLW MO No 60 (2021), PMD Act

USA: 21 CFR 820, 21 CFR 803, 21 CFR 806, 21 CFR 807 - Subparts A to D

The design, development and manufacture of in-vitro diagnostic reagents and their associated ancillaries, consumables, and test kits used in the diagnosis of cancer, disease status, endocrine disorders, genetic testing, protein metabolism, transmissible agents, and immunological typing.

For and on behalf of BSI:

Graeme Tunbridge, Senior Vice President Global Regulatory & Quality

Original Registration Date: 2019-03-04 Effective Date: 2025-02-26 Expiry Date: 2028-02-25

Page: 1 of 2

bsi.

MEDICAL

BSI Grou

MEDICAL DEVICE SINGLE AUDIT PROGRAM

BSI Group America Inc. is an MDSAP recognised auditing organization

...making excellence a habit."

Certificate No: MDSAP 696855

## Location Registered Activities

Leica Biosystems Newcastle Ltd Balliol Business Park West Benton Lane Newcastle upon Tyne NE12 8EW United Kingdom

Facility ID Number: F000261

Leica Biosystems Newcastle Ltd

2 Gosforth Park Way Newcastle NE12 8ET United Kingdom

Facility ID Number: F000261

The design, development and manufacture of in-vitro diagnostic reagents and their associated ancillaries, consumables, and test kits used in the diagnosis of cancer, disease status, endocrine disorders, genetic testing, protein metabolism, transmissible agents, and immunological typing.

The design and development of in-vitro diagnostic reagents, and their associated ancillaries, consumables, and test kits used in the diagnosis of cancer, disease status, endocrine disorders, genetic testing, protein metabolism, transmissible agents and immunological typing.



Original Registration Date: 2019-03-04 Effective Date: 2025-02-26 Expiry Date: 2028-02-25

Page: 2 of 2